US-12616847-B2 - Photodynamic therapy and microwave therapy fusion system

Abstract

A photodynamic therapy and microwave therapy fusion system is provided. The system includes photosensitizers transplanted or attached to the biological tissues of a site in which cancer develops, have specific indirect energy band gaps so as to perform photodynamic therapy for the site in which the cancer develops; and a microwave assisted photodynamic therapy (MWAPDT) controller connected to a personal computer (PC) and adapted to allow a microwave frequency of 5.3 GHz to 10 GHz emitted from a microwave probe or an optic ray emitted from a fiber optic probe to be irradiated onto the biological tissues of the site in which the cancer develops, to which the photosensitizers are attached, so as to perform microwave therapy for the site in which the cancer develops.

Inventors

• Nam-young Kim
• Eun-Seong Kim
• Maxim Alexandrovich PUGACHEVSKII

Assignees

• KWANGWOON UNIVERSITY INDUSTRY-ACADEMIC COLLABORATION FOUNDATION

Dates

Publication Date

20260505

Application Date

20230417

Priority Date

20220630

Claims (4)

1. 1 . A photodynamic therapy and microwave therapy fusion system comprising: one or more photosensitizers configured to be attached to the biological tissues of a site in which cancer develops, having specific indirect energy band gaps to perform photodynamic therapy for the site in which the cancer develops; and a microwave assisted photodynamic therapy (MWAPDT) controller connected to a personal computer (PC), wherein the MWAPDT controller controls an irradiation of a microwave frequency ranging from 5.3 GHz to 10 GHz emitted from a microwave probe, or controls an irradiation of an optic ray emitted from a fiber optic probe to be irradiated onto the biological tissues of the site in which the cancer develops, to which the one or more photosensitizers are configured to be attached, so as to perform microwave therapy for the site in which the cancer develops, wherein the cancer is solid cancer, wherein the one or more photosensitizers uses MeO 2 nanoparticles selected from the group consisting of ZrO 2 , HfO 2 , and combinations thereof, and wherein the MWAPDT controller is connected to the fiber optic probe, or the microwave probe and allows 0.01 mW to 10 W of power, a frequency of 5.3 GHz to 10 GHz of the microwave probe, to be irradiated onto the site in which the cancer develops, to which the one or more photosensitizers are attached, thereby killing cancer cells.
2. 2 . The system according to claim 1 , wherein the cancer includes one of skin cancer, stomach cancer, colorectal cancer, cervical cancer, kidney cancer, prostate cancer, breast cancer, brain tumor, lung cancer, liver cancer, uterine cervical cancer, colon cancer, bladder cancer, and pancreatic cancer.
3. 3 . The system according to claim 1 , wherein the MWAPDT controller is connected to the fiber optic probe, and the fiber optic probe comprises an operating button, a controller, a fiber optic driving circuit, and an optical fiber connected to a fiber optic driver and shielded in a longitudinal direction, so that the optic ray emitted from an optical fiber is irradiated onto the biological tissues of the site in which the cancer develops, to which the one or more photosensitizers are attached, to thus generate reactive oxygen species (ROS) or heat by the one or more photosensitizers thereby removing a target tumor locally.
4. 4 . The system according to claim 3 , wherein the MWAPDT controller is additionally connected to the microwave probe, and the microwave probe comprises an operating button, a controller, a battery, an RF generator having an oscillator, a modulator, a bandpass filter, and an amplifier, an RF transmitter, and an antenna, so that the optic ray and the microwave frequency of 5.3 GHz to 10 GHz are irradiated onto the biological tissues of the site in which the cancer develops, to which the one or more photosensitizers are attached, and the biological tissues become hot by ±phonons in an excitation band by the indirect energy band gaps and generate heat with a temperature of 41 to 46° C. to kill cancer cells, on the target tumor.

Description

CROSS-REFERENCE TO RELATED APPLICATION This application claims priority to Korean Patent Application No. 10-2022-0080469 filed on Jun. 30, 2022, in the Korean Intellectual Property Office, the entire disclosure of which is incorporated herein by reference. TECHNICAL FIELD The present invention relates to a photodynamic therapy and microwave therapy fusion system (hereinafter, referred to as PDTMTFS) capable of allowing photosensitizers having specific indirect energy band gaps to be attached to a target tumor to locally treat solid cancer and, under the control of a microwave assisted photodynamic therapy (hereinafter, referred to as MWAPDT) controller, making use of i) photodynamic therapy (PDT) in which the optic ray emitted from a fiber optic probe is irradiated onto the target tumor so that reactive oxygen species (ROS) or heat is generated primarily by the photosensitizers as photocatalysts to locally remove the target tumor, and ii) microwave therapy in which a microwave is generated from a microwave generator, a microwave transmitter, and an antenna of a microwave probe that irradiate a specific frequency of 5.3 GHz to 10 GHz to vibrate±phonons generated by the indirect energy band gaps from the photosensitizers and generate heat, so that the target tumor is removed and cancer metastasis and recurrence are prevented from occurring. The PDTMTFS is capable of making use of both of ROS and heat capable of inducing irreversible cancer cell death to prevent cancer metastasis and recurrence from occurring by anticancer drug resistance as a problem in a cancer treatment such as existing cancer chemotherapy, thereby providing more effective cancer therapy. BACKGROUND ART As the proportion of older people is increasing, the number of patients with cancer, cerebrovascular diseases, heart diseases, and diabetes is increasing. In specific, the high incidence rate of a brain tumor in cranial bone appears, i.e., in older patient order of the 50s, 60s, and 70s. Cancer is a leading cause of death worldwide, and cancer treatments such as surgery, chemotherapy, radiation therapy, immunotherapy, gene therapy, and the like have been developed. Further, the PDT has been introduced to treat all types of cancers. The PDT is a treatment in which light having a specific wavelength is absorbed to photosensitizers to thus generate ROS or heat in an excited state through an energy transfer mechanism, E=hv, so that the photosensitizers have chemical reactions with the ROS generated to allow free radicals generated by single oxygen to selectively kill cancer cells, without giving any pain to a patient, or to allow the heat generated from the photosensitizers to kill cancer cells. Recently, energy-based minimal invasive cancer therapy has been studied to kill a tumor being in a natural state. As the minimal invasive cancer therapy, photodynamic therapy (PDT) using optic ray and sono-dynamic therapy (SDP) using ultrasonic waves are used. The PDT is a treatment in which photosensitizers are injected into a body and laser light (optic ray) of a specific wavelength is irradiated onto an area to be treated, thereby treating a tumor. In this case, the PDT is selectively applied only to the area to be treated, has rare side effects, and is repeatedly performed, thereby improving surgical effectiveness. Further, the PDT can be performed, together with other therapies such as surgical therapy, radiation therapy, chemotherapy, and the like. One of conventional technologies relating thereto is disclosed in Korean Patent Publication Application No. 10-2021-0043472 entitled “Photosensitization transition materials for brain cancer treatment or brain cancer removal surgery, microwave microchip for inducing movement of brain cancer cell, and use thereof”. Another conventional technology relating thereto provides a transplantation composition in a tumor for cancer therapy, a transplantation kit having the same, and cancer therapy having the same, and in this case, the transplantation composition includes photosensitizers selected from the group consisting of TiO2, ZrO2, HfO2, and combinations thereof. The term “photosensitizers” used in the specification are substances that are excited when the optic ray having a specific wavelength is irradiated thereonto to generate a fluorescence signal or react with surrounding substrates or oxygen to produce the ROS. The produced ROS kill or necrotize surrounding cancer cells to provide local cancer therapy effectiveness. However, the existing photosensitizers may generate photosensitive reactions such as burn, edema, red spots, DNA mutation, and the like, and have difficulties in clinical application because of non-selective transfer to the tissues of a tumor. To solve these problems, the photosensitizers may be selected from the group consisting of CeO2, TiO2, ZrO2, HfO2, and combinations thereof. The conventional transplantation composition in a tumor is injected directly into a cancer tissue area or intr